(Q65541405)
Statements
A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (English)
0 references
September 2005
0 references
February 2008
0 references
835
0 references
18 year
0 references